explore -WSS

explore

author：comprehensive 2025-09-14 14:46:02 - browse：3242

The FDA building -- First Opinion coverage from STAT — Adobe

A panel of independent advisers to the Food and Drug Administration voted overwhelmingly against a polarizing potential treatment for ALS on Wednesday, concluding that the medicine’s messy supporting data did not meet the standard for approval.

After a day-long meeting that included impassioned testimony from ALS patients, the agency’s expert advisers voted 17-1 with one abstention that the case for NurOwn, a treatment from BrainStorm Cell Therapeutics, was based too heavily on convoluted clinical trial results and compelling but unreliable anecdotal evidence.

“Patients and families need hope, but providing false hope can be ethically problematic,” said panelist Lisa Lee, a bioethicist at Virginia Tech. “False hope is provided when the probability of a positive outcome is overestimated, and I think that seems to be the case here.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Kim Kardashian sparks debate on benefits of full

explore

focus

WSS

Who are the detained American citizens released from prison in Iran?

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

An innovative path out of biotech’s “valley of death”

Target recalls 2.2 million additional candles due to laceration, burn hazards

Eli Lilly’s Mounjaro succeeds in second weight

Listen: Your guide to Wegovy's blockbuster heart study

knowledge

explore

Wikipedia

Malaria cases in Florida and Texas: Here’s what you need to know

A public health expert passes on football's full body collisions for youths

State Dept. review finds Biden bears some blame for Afghanistan failures

Novo pauses ads for weight loss drug Wegovy amid demand

Anesthesiologist group: stop taking Ozempic before surgery

Patients, doctors are clashing about side effects of hormonal birth control

Anesthesiologist group: stop taking Ozempic before surgery

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

DIEP, the 'gold standard' of breast reconstruction, is under threat

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

hotspot

Bispecific antibodies are next new thing in cancer immunotherapy

Newly revealed memo details efforts to keep Trump in power following election loss

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Maui funeral service workers on devastation of fires: 'I'm in shock'

Mom launches Girl Scout troop for LGBTQ youth in Texas

Sea level rise could wash away turtle breeding grounds around the world, researchers say

explore

knowledge

focus

focus